Rates of Major Cardiovascular Events in Severe Asthma: U.S. Real-World and Clinical Trial-Eligible Populations
Ann Am Thorac Soc
.
2021 Sep;18(9):1580-1584.
doi: 10.1513/AnnalsATS.202010-1349RL.
Authors
Parul Dayal
1
,
Carlos Iribarren
2
,
Dorothy Cheung
1
,
Michael E Rothenberg
1
,
C Victor Spain
1
Affiliations
1
Genentech Inc. South San Francisco, California.
2
Kaiser Permanente Northern California Oakland, California.
PMID:
33606957
PMCID:
PMC8489874
DOI:
10.1513/AnnalsATS.202010-1349RL
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Anti-Asthmatic Agents* / therapeutic use
Asthma* / drug therapy
Asthma* / epidemiology
Cardiovascular Diseases* / epidemiology
Humans
Substances
Anti-Asthmatic Agents